Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Text Rev. Washington (DC): American Psychiatric Association; 2022.
   Google Scholar
• Faraone SV. Attention deficit hyperactivity disorder and premature death. Lancet. 2015;385(9983):2132–2133. doi: 10.1016/S0140-6736(14)61822-5.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry. 2006;163(4):716–723. doi: 10.1176/appi.ajp.163.4.716.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62(6):593–602. doi: 10.1001/archpsyc.62.6.593.
   PubMed Web of Science ®Google Scholar
• Caye A, Swanson JM, Coghill D, et al. Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Mol Psychiatry. 2019;24(3):390–408. doi: 10.1038/s41380-018-0116-3.
   PubMed Web of Science ®Google Scholar
• Post RE, Kurlansik SL. Diagnosis and management of adult attention-deficit/hyperactivity disorder. Am Fam Physician. 2012;85(9):890–896.
   PubMed Web of Science ®Google Scholar
• Schein JC, Gauthier-Loiselle M, Catillon M, Childress A, editor Assessment of centanafadine in adults with ADHD: a matching adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended release. Baltimore (MD): ASHP; 2023.
   Google Scholar
• Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543–1569.
   PubMed Web of Science ®Google Scholar
• Schein J, Childress A, Adams J, et al. Treatment patterns among adults with attention-deficit/hyperactivity disorder in the United States: a retrospective claims study. Curr Med Res Opin. 2021;37(11):2007–2014. doi: 10.1080/03007995.2021.1968814.
   PubMed Web of Science ®Google Scholar
• Adler LA, Farahbakhshian S, Romero B, et al. Healthcare provider perspectives on diagnosing and treating adults with attention-deficit/hyperactivity disorder. Postgrad Med. 2019;131(7):461–472. doi: 10.1080/00325481.2019.1647080.
   PubMed Web of Science ®Google Scholar
• Daley D, Jacobsen RH, Lange AM, et al. The economic burden of adult attention deficit hyperactivity disorder: a sibling comparison cost analysis. Eur Psychiatry. 2019;61:41–48. doi: 10.1016/j.eurpsy.2019.06.011.
   PubMed Web of Science ®Google Scholar
• Lee L, Arunajadai S, Mikl J, et al. The burden of attention-deficit/hyperactivity disorder in adults: a real-world linked data study. Prim Care Companion CNS Disord. 2023;25(2):22m03348. doi: 10.4088/PCC.22m03348.
   PubMedGoogle Scholar
• Schein J, Adler LA, Childress A, et al. Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective. J Manag Care Spec Pharm. 2022;28(2):168–179. doi: 10.18553/jmcp.2021.21290.
   PubMed Web of Science ®Google Scholar
• Witrick B, Zhang D, Su D, et al. Medical expenditures associated with Attention-Deficit/hyperactivity disorder among adults in the United States by age, 2015-2019. J Gen Intern Med. 2023;38(9):2082–2090. doi: 10.1007/s11606-023-08075-w.
   PubMed Web of Science ®Google Scholar
• Adler LA, Adams J, Madera-McDonough J, et al. Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder: results of 2 phase 3, randomized, double-blind, multicenter, placebo-controlled trials. J Clin Psychopharmacol. 2022;42(5):429–439. doi: 10.1097/JCP.0000000000001575.
   PubMed Web of Science ®Google Scholar
• Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364–1373. doi: 10.4088/jcp.v69n0903.
   PubMed Web of Science ®Google Scholar
• Adler LA, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol. 2009;29(1):44–50. doi: 10.1097/JCP.0b013e318192e4a0.
   PubMed Web of Science ®Google Scholar
• Nasser A, Hull JT, Chaturvedi SA, et al. A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit/hyperactivity disorder. CNS Drugs. 2022;36(8):897–915. doi: 10.1007/s40263-022-00938-w.
   PubMed Web of Science ®Google Scholar
• Hainmueller J. Entropy balancing for causal effects: a multivariate reweighting method to produce balanced samples in observational studies. Polit Anal. 2012;20(1):25–46. doi: 10.1093/pan/mpr025.
   Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for behavioural sciences. 2nd ed. New York, NY: Routledge; 1988.
   Google Scholar
• Wong W, Yim YM, Kim A, et al. Assessment of costs associated with adverse events in patients with cancer. PLoS One. 2018;13(4):e0196007. doi: 10.1371/journal.pone.0196007.
   PubMed Web of Science ®Google Scholar
• Doshi JA, Hodgkins P, Kahle J, et al. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry. 2012;51(10):990 e2–1002 e2. doi: 10.1016/j.jaac.2012.07.008.
   PubMed Web of Science ®Google Scholar
• Weibel S, Menard O, Ionita A, et al. Practical considerations for the evaluation and management of attention deficit hyperactivity disorder (ADHD) in adults. Encephale. 2020;46(1):30–40. doi: 10.1016/j.encep.2019.06.005.
   PubMed Web of Science ®Google Scholar
• Schein J, Cloutier M, Gauthier-Loiselle M, et al. Symptoms associated with ADHD/treatment-related adverse side effects and their impact on quality of life and work productivity in adults with ADHD. Curr Med Res Opin. 2023;39(1):149–159. doi: 10.1080/03007995.2022.2122228.
   PubMed Web of Science ®Google Scholar
• Kis B, Lücke C, Abdel-Hamid M, et al. Safety profile of methylphenidate under long-term treatment in adult ADHD patients - results of the COMPAS study. Pharmacopsychiatry. 2020;53(6):263–271. doi: 10.1055/a-1207-9851.
   PubMedGoogle Scholar
• Schein J, Childress A, Cloutier M, et al. Reasons for treatment changes in adults with attention-deficit/hyperactivity disorder: a chart review study. BMC Psychiatry. 2022;322(1):377. doi: 10.1186/s12888-022-04016-9.
   PubMed Web of Science ®Google Scholar
• Keehan SP, Cuckler GA, Sisko AM, et al. National health expenditure projections, 2014-24: spending growth faster than recent trends. Health Aff. 2015;34(8):1407–1417. doi: 10.1377/hlthaff.2015.0600.
   Web of Science ®Google Scholar